tbuckley/cabot-search huggingface dataset:
PTU-148 Efficacy of early Cancer Screening in Barrett’S Oesophagus
Authors: J Faulkner, R Ley Greaves, J Hoare
Journal: Gut (2013)

<h3>Introduction</h3> The British Society of Gastroenterology recommends biennial endoscopic screening of patients with known Barrett’s. Despite being widely employed the efficacy of surveillance is contested as the assumed 0.5% per year progression from metaplasia to cancer is disputed.(1) This study aims to evaluate the efficacy of detection of Barrett’s related cancer through screening within the Imperial College NHS Trust. <h3>Methods</h3> We retrospectively analysed endoscopy and pathology reports of all patients who received an endoscopy for Barrett’s oesophagus within a 5 year period from 2007 to 2012. Patients presenting with established dysplasia or adenocarcinoma were excluded and only those with confirmed Barrett’s oesophagus were considered. The surveillance regime in this period was in accordance with the British Society of Gastroenterology guidelines. All endoscopies were conducted by Imperial College NHS gastroenterologists within Imperial Trust sites. <h3>Results</h3> Over 54 months 326 patients underwent endoscopic surveillance of Barrett’s oesophagus with a mean follow-up of 36 months. 73 (22%) patients stopped surveillance in this period. Early Adenocarcinoma and High Grade Dysplasia was reported in 2 (0.6%) and 3 (0.9%) patients respectfully. Providing a 0.2% progression to adenocarcinoma per year and a 0.5% progression to High Grade Dysplasia or cancer per year. This gave a cancer incidence in Barrett’s oesophagus of 1 per 492 patient years of surveillance. All three of the HGD patients underwent endoscopic therapy and have successfully eradicated dysplasia and Barrett’s. Both cancer patients were unsuitable for endoscopic therapy. 1 received surgical treatment and 1 received radiotherapy. <h3>Conclusion</h3> The risk of progression to cancer is lower than previously anticipated. We estimate the cost of a single surveillance endoscopy at £400, thus surveillance costs are £124,000 per cancer diagnosis. The mean age of adenocarcinoma diagnosis through surveillance is 68.1(2) and with average male life expectancy of 78, the cost of diagnosis is approximately £12,400 per year saved. This assumes all cancers detected via surveillance are curable and does not account for any subsequent treatment or follow-up costs, therefore this is likely to be a fractiont of the true cost. NICE state that £20,000-£30,000 is a cost-effective range per quality adjusted life year saved. In light of this we recommend a more stratified, cost effective screening programme be considered. <h3>Disclosure of Interest</h3> None Declared <h3>References</h3> Kahrilas PJ. The Problems with Surveillance of Barrett’s Esophagus. <i>The New England journal of medicine</i><i></i> 2011; 365(15): pp. 1437–1438. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s oesophagus. <i>New England Journal of Medicine</i><i></i> 2011; 365(15): pp. 1375–1383.
OP0033 Classification Criteria for Systemic Sclerosis: Preliminary Results
Authors: F. Van Den Hoogen, D. Khanna, J. Fransen, S. R. Johnson, M. Baron, A. Tyndall, M. Matucci, R. Naden, J. Pope
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> The existing 1980 classification criteria for systemic sclerosis (SSc) are suboptimal for patients with early SSc and some patients with limited cutaneous SSc (lcSSc) where an important subset do not meet those criteria. <h3>Objectives</h3> To develop and test new classification criteria for SSc by a joint EULAR and ACR committee. <h3>Methods</h3> Delphi exercises and a nominal group technique were used to create a set of potential items for classification of SSc. Twenty cases were prospectively collected to represent the spectrum of SSc (low probability to high probability) which were ranked by SSc experts and conjoint analysis (1000 Minds®) was used to assign weights to the items and reduce the number of items. Experts agreed that all patients with sclerodactyly and scleroderma skin involvement proximal to the MCPs were considered SSc; patients with skin involvement due another scleroderma-like disorder (e.g. scleromyxedema) or skin thickening sparing the fingers were not regarded to have SSc. The provisional classification system was tested in a random sample of SSc cases and controls of 100 from North America and 100 from Europe (derivation sample). The system was simplified and calibrated to real cases. The classification system was re-analyzed in another sample of SSc cases and controls (validation set; n=405). <h3>Results</h3> The table provides the final items with the proposed weights. Only the maximum score in each domain is counted. A cut-off of &gt;= 9 (out of 19) had a sensitivity of 91% and specificity of 92% in the validation cohort (n=405). The sensitivity and specificity of the former 1980 ARA criteria in this database were 75% and 72%, respectively. These results are preliminary and not yet approved by the organizational sponsors. <h3>Conclusions</h3> The preliminary results of the classification criteria for SSc performed better than 1980 Preliminary ARA Criteria for SSc. These criteria can be endorsed for epidemiological studies and clinical trials after approval by ACR and EULAR. <h3>Disclosure of Interest</h3> None Declared
ESTIMATED PREVALENCE OF POSSIBLE AND PROBABLE FAMILIAL HYPERCHOLESTEROLEMIA IN 35,451 STATIN-TREATED PATIENTS IN EUROPE, CANADA, THE MIDDLE EAST, AND SOUTH AFRICA
Authors: Anselm K. Gitt, Dominik Lautsch, Baishali Ambegaonkar, Martin Horack, Jean Ferrières
Journal: Journal of the American College of Cardiology (2016)
Abstract LB-106: Inhibition of glycolysis with 2-deoxyglucose inhibits spontaneous metastasis in murine osteosarcoma
Authors: Douglas H. Thamm, Janet Lori, Joseph L. Sottnik
Journal: Cancer Research (2010)

Abstract We recently reported on a re-analysis of previously published gene expression data from a large set of primary solid and metastatic tumors originating from different tissues using the latest available tools for normalization, identification of differentially expressed genes and pathway analysis (Ptitsyn A., et al, BMC Bioinformatics 2008;9 Suppl: S8). Analysis of multiple independent datasets indicated significantly reduced oxidative phosphorylation in metastases compared to primary solid tumors, implying a potential enhancement of the Warburg phenotype in metastatic progression. We thus sought to determine if inhibition of anaerobic glycolysis with the competitive inhibitor 2-deoxy-D-glucose (2-DG) would reverse this metastatic bioenergetic phenotype in highly metastatic cancer cells. We evaluated the effects of 2-DG on DLM8 osteosarcoma cell migration and Matrigel invasion via Boyden chamber assays, and modulation of in vitro production of matrix metalloproteases, VEGF, and cathepsin L were evaluated by gelatin zymography, ELISA and western analysis respectively. The effects of 2-DG administration in vivo was evaluated in an orthotopic, spontaneously metastatic, luciferase-transfected postsurgical model of murine osteosarcoma utilizing DLM8, which is syngeneic to C3H mice. DLM8 cells were implanted into the distal tibias of C3H mice, followed by amputation of the affected limb 16 days later. 2-DG or saline were administered postoperatively (500 mg/kg IP 3x/week, n=5 per group) until sacrifice. Presence of metastasis was evaluated using biweekly bioluminescence imaging and metastasis-free interval calculated using the Kaplan-Meier method. Concentrations of 2-DG associated with minimal antiproliferative activity dramatically inhibited DLM8 cell migration and invasion. There was a dose-dependent decrease in cathepsin L expression upon 2-DG exposure, and VEGF production was inhibited at high 2-DG concentrations, but there were no repeatable changes in MMP activity within the concentration range associated with inhibition of migration and invasion. Postoperative administration of 2-DG significantly delayed DLM8 metastasis (median metastasis-free interval 8 vs 34 days, p = 0.049). In conclusion, glycolysis inhibition with 2-DG is associated with an inhibition of osteosarcoma migration, invasion and in vivo metastasis, at concentrations associated with minimal antiproliferative activity. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-106.
Prospective Study of Ice Gel Pack as Less Expensive Alternative for Prevention of Skin and Nail Toxicity in Patients with Breast Cancer Receiving Docetaxel.
Authors: K. Matsumoto, C. Hino, K. Fukuda, M. Hamamoto, M. Tanioka, K. Hirokaga, Y. Maekawa, S. Negoro, S. Takao
Journal: Cancer Research (2009)

Abstract Background: Docetaxel (DTX)-induced nail and skin toxicity can be prevented by frozen glove. We investigate whether we can use cooling gel pad (CGP), which is available less than 10 dollars in Japan, as less expensive alternative.Method: Patients (pts) with breast cancer receiving DTX as preoperative or post operative chemotherapy were eligible for this study. Two CGPs, which were refrigerated for eight hours beforehand, were used to cover patient's hand from 15 minutes before to 15minutes after DTX administration. To reduce discomfort from icing, pts were wearing cotton glove during CGP usage. If pts felt CGP as too cold during the cooling process, they were allowed to remove CGP tentatively until they felt comfort. Another hand was not covered as the control. Nail and skin toxicity were assessed at each cycle by CTCAEver.3.0 and documented by photography. Fisher's exact probability test was used. Satisfaction and discomfort of CGP covering was assessed by pts using two item questionnaires. All patients gave written informed consent. The protocol was approved by institutional review board.Result: From October 2006 to September 2008, 50 pts were enrolled to this study. All the patients were female, and received DTX 75mg/m2 in every three weeks schedule for four cycles. Most of patients received DTX after anthracycline-containing regimen. Both nail (10% v 66%, p&amp;lt;0.0001) and skin (0% v 34%, p&amp;lt;0.0001) toxicity was reduced in CGP covered hands. Nail toxicity was grade (G) 0 in 90% v 34%, G1 in 10% v 42%, G2 in 0% v 22%, and G3 in 0% v 2%, for CGP covered and the control hand, respectively. Skin toxicity was G0 in 100% v 66%, G1 in 0% v 4%, G2 in 0% v 30% in CGP covered hand and the control hand, respectively. About the timing of toxicity occurrence, “after the first cycle” was most common, 13 pts (39%) in nail change and 7 pts (41%) in skin toxicity. In the questionnaires, 94% were satisfied with CGP covering.Discussion: The iced CGP cover method reduced the incidence and severity of nail and skin toxicity associated with DTX, even if patients wear cotton glove and remove CGP for a while, in case of excess coldness. This method has no adverse effect, and patients were satisfied with the effect. The iced CGP may be considered as a new, effective and less expensive method for prevention of nail and skin toxicity caused by DTX. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1114.
Quantitative Analysis of In-111 Satumomab Pendetide Immunoscintigraphy
Authors: Charles E. Neal, Darrin L. Johnson, Vicki L. Cornwell, Steve Markwell
Journal: Clinical Nuclear Medicine (1996)

The diagnosis of the diffuse intrapertioneal spread of ovarian or colorectal carcinoma (carcinomatosis) can be difficult when based on visual interpretation of immunoscintigraphic images alone. Twenty-nine patients with either colorectal or ovarian cancer were retrospectively evaluated by three technologists for carcinomatosis employing a quantitative analysis technique that compares uptake of In-111 satumomab pendetide (Oncoscint CR/ OV, Cytogen Corp., Princeton, NJ) in a region of interest in the femoral vascular bundle to the uptake in two regions of interest in the lower abdomen, resulting in an uptake ratio (UR). All 29 patients underwent laparotomy after immunoscintigraphy. Of the 29 patients evaluated, 7 had histologically proven carcinomatosis obtained from the laparotomy. Using quantitative analysis, patients who did not have carcinomatosis had a mean uptake ratio of 1.12, and patients with carcinomatosis had a mean uptake ratio of 2.12. The differences between the means of these two groups of patients was statistically significant for all three technologists (P < .05). The results of this study indicate that there is a significant difference in uptake ratios between patients with carcinomatosis and those without it, and that quantitative analysis can be a useful adjunct to visual interpretation.
Stat Bite: Prostate Cancer Treatment and Health Care Source
Authors: H. P. Greenwald
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article Stat Bite: Prostate Cancer Treatment and Health Care Source Get access Howard P. Greenwald, Ph.D. Howard P. Greenwald, Ph.D. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 1, 6 January 1993, Page 11, https://doi.org/10.1093/jnci/85.1.11-a Published: 06 January 1993
To Publish or Not to Publish...
Authors: W. K. Alfred Yung
Journal: Neuro-Oncology (2008)

In the ideal, research would always be transformative, yielding information that immediately and directly improves not just a discipline-specific knowledge base but the human condition as well.In the real world, of course, research represents an accumulation of experiences and incremental gains, which together ultimately reveal what we really want to know.Conducting research is most often like putting together the pieces of a 1,000-plus-piece puzzle: each one seems to contribute just a little information to the whole, but if any one of those pieces is missing, the picture is incomplete.Neuro-Oncology is a journal that serves both a large constituency (those interested and involved in the umbrella concept of "neuro-oncology") and those working in the subspecialties that individually contribute information to the whole.With the rise in our impact factor and our now one-year-old practice of bimonthly publication, submissions to the journal and the quality of those submissions are at an all-time high.One of the more difficult tasks for journal editors (and the peer reviewers who provide critiques on the submissions) is to determine which manuscripts merit publication.The hard truth is that sometimes even good papers, those that in themselves describe robust results gained from welldesigned inquiries, may not make it into our pageswhether because of space constraints, timeliness, or the scope of content.
Abstract 4122: Induction of steroid sulfatase expression by bacterial lipopolysaccharides in human prostate cancer cells: Possible role of STS in tumor cell migration
Authors: Hee-Jung Im, Nahee Park, Young-Jin Chun
Journal: Cancer Research (2012)

Abstract Steroid sulfatase (STS) is responsible for the conversion of estrone sulfate to estrone that can stimulate growth in endocrine-dependent tumors such as breast and prostate cancer. Although STS is considered as a therapeutic target for the estrogen-dependent diseases, cellular function of STS are still not clear. Previously, we found that tumor necrosis factor (TNF)-α significantly enhances steroid sulfatase expression in PC-3 human prostate cancer cells through PI3K/Akt-dependent pathways. Here, we studied whether bacterial lipopolysaccharides (LPS) which are known to induce TNF-α may increase STS expression. Treatment with LPS in PC-3 cells induces STS mRNA and protein in concentration- and time-dependent manners. Because LPS-induced STS mRNA expression was strongly suppressed by NF-κB inhibitors such as Bay 11-7082 and bortezomib, the involvement of NF-κB pathways on STS expression was suggested. To determine whether IkBα is involved in NF-κB-dependent STS expression, the effect of IKKα siRNA was elucidated. IKKα siRNA significantly suppressed STS mRNA and protein expression. Interestingly, overexpression of STS by transfecting expression vector induced wound healing effect whereas knockdown of STS by siRNA significantly decreased wound healing effect in PC-3 cells. Moreover, treatment with LPS in STS knockdowned cells recovered wound healing effect. Taken together, these results strongly suggest that STS may contribute tumor cell migration. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4122. doi:1538-7445.AM2012-4122
A SYSTEMATIC APPROACH TO VISUAL ESTIMATION OF LEFT VENTRICULAR EJECTION FRACTION.
Authors: M. B. Brachman, D. S. Berman, L. Roy, L. Ramanna, D. E. Tanasescu, A. D. Waxman, J. Maddahi
Journal: Clinical Nuclear Medicine (1987)

Brachman, M. B.; Berman, D. S.; Roy, L.; Ramanna, L.; Tanasescu, D. E.; Waxman, A. D.; Maddahi, J. Author Information
Too early to attach blanket health warnings to all drugs containing sodium, irrespective of conjugate anion
Authors: O. F. Uzoigwe
Journal: BMJ (2014)

<h3>Background</h3> Patients with MND are at risk of respiratory compromise due to chest wall weakness and require NIV. As prognosis is short this should be a rapid referral to respiratory services. We advise that time between referral and assessment should be aimed at &lt;6 weeks. <h3>Methods</h3> Neurorehabilitation team lead supplied the details of eight MND patients referred for NIV assessments to Colchester Hospital (CHUFT) within the last twelve months. The usual referral pathway is via Papworth Hospital Cambridge but these patients were either too unwell or had chosen not to travel to Cambridge for assessment. A review of the patient‘s paper notes, Order comms system, Electronic Discharge Summaries, Respiratory clinic letter database and the separate patient neurorehab notes was undertaken. <h3>Results</h3> One patient has been managed by Basildon Hospital so excluded from the audit which focused on CHUFT services. Of the seven remaining patients, two have not been seen by respiratory services as yet and the reason is unclear. One patient was admitted to Colchester General Hospital with life threatening respiratory compromise two months after referral and started NIV therefore as an inpatient. The final four patients were seen at 13 days, 6 weeks and (2x) 4 months post referral. <h3>Conclusion</h3> There is no standard best practice process for managing these referrals. The NICE quality standard does not advise the time by which these patients should be assessed by respiratory services post referral. The tests required also could be standardised. At present it is not clear whether they require an arterial blood gas or sleep study. It might also be possible to start NIV and assess symptomatic benefit without tests. Writing agreed local guidelines would therefore be beneficial. In light of the patients short prognosis with MND it might advisable to aim for review in &lt;6 weeks.
Henoch–Schönlein Purpura
Authors: Mark A Marinella
Journal: New England Journal of Medicine (2004)

A 20-year-old man was admitted to the hospital with a one-day history of fever and acute, painful symmetric polyarthritis that involved the wrists, elbows, and ankles. During the next two days, edema and palpable purpura developed over the dorsal aspect of the hands and feet (Panels A and B), as well as on the buttocks and legs. Severe abdominal pain with hematemesis developed, along with an increase in liver aminotransferase levels. Henoch–Schonlein purpura was suspected. Computed tomographic scanning of the abdomen revealed edema of the small intestine, a finding consistent with the presence of intestinal vasculitis. Examination of a biopsy . . .
113 A PROSPECTIVE RANDOMIZED TRIAL COMPARING HDR-BRACHYTHERAPY AND TRANSARTERIAL CHEMOEMBOLIZATION IN HEPATOCELLULAR CARCINOMA
Authors: K. Mohnike, M. Pech, M. Seidensticker, R. Seidensticker, T. Bretschneider, K. Schuette, C. Schulz, P. Malfertheiner, J. Ricke
Journal: Journal of Hepatology (2013)
FRI0171 Does Rheumatoid Arthritis Protect against Multiple Sclerosis, and IF So, When? A Population-Based Study:
Authors: E. Arkema, T. Frisell, T. Olsson, J. Askling
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Experimental data suggest shared susceptibilities but also an “either or” pattern of risk for RA and multiple sclerosis (MS). Observational data have suggested a possible reduced occurrence of MS among patients with RA [1]. Other reports have suggested a possible increase in the occurrence of demyelinating events in RA treated with TNF inhibitors [2]. A proper understanding of the co-occurrence of RA and MS is thus both of etiological and clinical importance. <h3>Objectives</h3> Our aim was to estimate the risk of RA among patients who had had a demyelinating event and/or MS, and the risk of MS/demyelinating events in patients with prior RA diagnosis, compared to the general population. <h3>Methods</h3> Cases with incident RA were identified from the national patient register (NPR; Swedish inpatient and outpatient care) and the Swedish Rheumatology Quality Register (SRQ). General population comparators were selected from the Swedish population register matched to the RA patients by age, sex and county. Data on demyelinating disease and MS among RA patients and their population comparators were extracted from the NPR. We used logistic regression models to calculate the odds ratio (OR) of having a history of MS by the time of RA diagnosis, and Cox regression models to calculate the hazard ratio (HR) of MS following RA diagnosis, in both analyses compared to the general population. <h3>Results</h3> We included 8,170 incident RA cases from SRQ and 40,728 general population matched controls. The OR for RA associated with a history of MS was 0.68 (95%CI; 0.38, 1.21) and the OR for RA associated with a history of a demyelinating event was 0.48 (95%CI; 0.17, 1.32). Counting from RA diagnosis and onwards, we observed only 1 MS case in the RA population and 24 MS cases among the population comparators, corresponding to a HR=0.26 (95%CI 0.04, 1.97). RA was associated with an increased risk of subsequent demyelinating event (HR 2.59 95%CI 1.24, 5.39). When the same analyses were performed using RA identified in the Patient Register, numbers increased but all associations remained of similar strength. <h3>Conclusions</h3> The risk of RA among patients with a history of MS was reduced by a third. Cases of MS after RA onset were rare, suggesting shared but opposing or exclusive susceptibilities of the two diseases. By contrast, the risk for demyelinating events was reduced before RA onset, but not thereafter, indicating a cause-and-effect association with the RA disease. <h3>References</h3> Somers EC, Thomas SL, Smeeth L, Hall AJ. Are Individuals With an Autoimmune Disease at Higher Risk of a Second Autoimmune Disorder? Am J Epidemiol 2009;169:749-55. Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-alpha therapy: a French national survey. Rheumatology (Oxford) 2013;52:868-74. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4579
GW25-e1531 Comparison of repeated drug eluting stent for treatment of early and late in-stent restenosis after drug eluting stent implantation
Authors: Zhao Lin, Zhu Weiwei, Guo Chengjun, Fang Dongping, Hao Peng, Chi Yunpeng, Zhang Xiaojiang, Li Qiaoyuan, Wang Guozhong, Wu Xiaofan, Liu Meiyan, Zhao Lin
Journal: Journal of the American College of Cardiology (2014)